1P-ETH-LAD

# Research Output: 1P-ETH-LAD

---

## Chemical Identity

**Verified chemical data (PubChem CID 119025859 [Ref 1-PubChem]):**

| Field | Value |
|---|---|
| IUPAC name | (6aR,9R)-N,N,7-triethyl-4-propanoyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide |
| Molecular formula | C₂₄H₃₁N₃O₂ |
| Molecular weight | 393.5 g/mol |
| InChIKey | MLOFCBXSOAYCIF-DYESRHJHSA-N |
| CAS number | 2230715-45-2 |
| PubChem CID | 119025859 |

**SMILES:** Not returned by PubChem API call; not included in brief seed data. This is a gap — the generation agent should retrieve SMILES from PubChem's full record for CID 119025859.

**Seed data consistency:** The brief's IUPAC name — `(6aR,9R)-N,N,7-triethyl-4-propanoyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide` — matches the PubChem record exactly. Molecular formula C₂₄H₃₁N₃O₂ and MW 393.5 g/mol are confirmed. InChIKey and CID were absent from the brief but are now verified.

**Cross-check note:** The systematic name in the brief (`(6aR,9R)-N,N,7-triethyl-4-propanoyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide`) uses the hexahydro tautomer notation and matches PubChem. The alternate IUPAC form seen in some literature uses the full hexahydroindoloquinoline ring designation. Both refer to the same compound.

---

## Pharmacology

### Mechanism of Action and Receptor Profile

1P-ETH-LAD is understood to function as a **prodrug for ETH-LAD** (N⁶-ethyl-6-nor-LSD, or N⁶-ethylnorlysergic acid N,N-diethylamide). In vitro serum hydrolysis studies demonstrated conversion of 1P-ETH-LAD to ETH-LAD in human serum at 37°C within a 24-hour window, suggesting that the N-1 propionyl group is cleaved under physiological conditions to release the active compound (Brandt et al. 2017 [Ref 1]).

The active metabolite **ETH-LAD** is a non-selective serotonin receptor ligand. Based on data from Hoffman and Nichols (1985 [Ref 16]), ETH-LAD's key receptor binding affinities include:

- **5-HT₂A receptor**: Ki ≈ 5.1 nM (high affinity partial agonist; primary receptor mediating psychedelic effects)
- **Dopamine D2 receptor**: Ki ≈ 4.4 nM
- **5-HT₁A receptor**: high affinity (Ki data specific to ETH-LAD not retrieved; LSD Ki ~3–5 nM for 5-HT₁A by analogy)
- **5-HT₂C receptor**: high affinity binding (quantitative Ki not retrieved from published sources for ETH-LAD specifically)
- **Dopamine D1, D3, D4, D5 receptors**: lower affinity binding

**⚠️ FLAG — Human review required:** Specific ETH-LAD Ki values cited above (5-HT₂A 5.1 nM, D2 4.4 nM) were retrieved from secondary web sources (MedChemExpress) citing Hoffman & Nichols 1985 [Ref 16], a paper verified by DOI but not retrieved in full text. These values should be cross-checked against the original journal article before use in article prose.

#### 1P-ETH-LAD's Own Receptor Affinity

Halberstadt et al. (2020 [Ref 4]) demonstrated that **1-acyl substitution reduces monoamine receptor affinity by 1–2 orders of magnitude** compared to the parent lysergamide, for a range of 1-acyl LSD derivatives (ALD-52, 1P-LSD, 1B-LSD). By analogy, 1P-ETH-LAD is expected to have substantially reduced affinity at 5-HT₂A and D2 compared to ETH-LAD, acting primarily as an inactive precursor until hydrolysis occurs. **No direct receptor binding data for 1P-ETH-LAD itself has been published** — this section relies on structural analogy with 1B-LSD (the constitutional isomer; Brandt et al. 2019 [Ref 3]) and the 1-acyl class findings of Halberstadt et al. (2020 [Ref 4]).

#### Primary Mechanism

The principal psychedelic mechanism of ETH-LAD (and by extension 1P-ETH-LAD after prodrug conversion) is **5-HT₂A receptor partial agonism**, mediating alterations in perception and cognition (Cummins et al. 2025 [Ref 20]; Wallach et al. 2023 [Ref 19]). The Gq-coupled signaling pathway (not β-arrestin2) is the primary driver of psychedelic behavioral effects, as demonstrated for the hallucinogen class (Wallach et al. 2023 [Ref 19]; Kim et al. 2020 [Ref 34]).

Additional mechanisms include:
- **5-HT₁A partial agonism**: may modulate or attenuate psychedelic effects (Brandt et al. 2018 [Ref 9], demonstrating that 5-HT₁A activation can mask 5-HT₂A-mediated HTR in a related lysergamide)
- **Dopamine D2 agonism**: contributes to stimulant and cognitive aspects; part of the multi-target ergoline pharmacology
- **D2–5-HT₂A heteroreceptor complex**: LSD-class hallucinogens enhance D2 protomer recognition through allosteric 5-HT₂A activation (Borroto-Escuela et al. 2014 [Ref — see interactions section])

ETH-LAD's N⁶-ethyl substitution at the ring nitrogen (replacing the N-methyl of LSD) appears to produce moderately enhanced potency relative to LSD in some systems, though the 2017 survey data (Coney et al. [Ref 17]) found subjective effects slightly less intense than LSD at equivalent doses. The Hoffman & Nichols 1985 paper [Ref 16] established LSD-like discriminative stimulus properties for ETH-LAD.

### Metabolism

**In vitro human serum data:**
The N-1 propionyl group of 1P-ETH-LAD undergoes hydrolysis in human serum at 37°C to yield ETH-LAD as the primary product (Brandt et al. 2017 [Ref 1]). 1P-ETH-LAD remained detectable in serum for at least 24 hours post-incubation, indicating incomplete conversion at that timepoint. No kinetic rate constants for the hydrolysis reaction were reported for 1P-ETH-LAD specifically.

**In vitro S9 fraction metabolism:**
Wagmann et al. (2019 [Ref 2]) characterized the metabolism of 1P-ETH-LAD using pooled human liver S9 fraction:
- Primary metabolic pathways: **N-dealkylation and hydroxylation**, and combinations thereof
- Principal CYP enzymes: **CYP1A2 and CYP3A4** (confirmed by recombinant enzyme studies and inhibition experiments)
- Unlike ALD-52, 1P-LSD, and 1B-LSD — where deacylation to LSD was explicitly observed — for 1P-ETH-LAD the study described deacylation to ETH-LAD (consistent with prodrug hypothesis)
- Parent drug and metabolites were **not detectable in rat urine at expected recreational doses** using standard urinalysis procedures

**CYP2D6 context:** For the closely related LSD, CYP2D6 genotype significantly influences pharmacokinetics: poor metabolizers show ~75% higher AUC and prolonged effects (Vizeli et al. 2021 [Ref 15]). Multiple CYPs (CYP2D6, CYP1A2, CYP2C9) are involved in LSD metabolism in vitro. By analogy, CYP2D6 may influence ETH-LAD clearance after 1P-ETH-LAD hydrolysis, but no direct pharmacogenetic data exist for ETH-LAD or 1P-ETH-LAD.

### Pharmacokinetics

**No published human pharmacokinetic data exists for 1P-ETH-LAD or ETH-LAD.**

The available prodrug analog data (from 1P-LSD, the closest structural analog) provides inference:
- Oral 1P-LSD (100 µg): only LSD was detectable in serum/urine (Grumann et al. 2020 [Ref 11]); LSD elimination t₁/₂ ≈ 6.4 h
- Bioavailability of the active form from oral 1P-LSD was approximately 100% (Grumann et al. 2020 [Ref 11])
- LSD oral bioavailability (as free base or tartrate) is approximately 80% (Arikci et al. 2025 [Ref 35])

Duration data (from community survey): Coney et al. (2017 [Ref 17]) found a modal total duration of 8 hours for LSD analogue users (pooled group including ETH-LAD users), which is consistent with ETH-LAD's known profile (8–12 hours per PsychonautWiki community consensus) compared to LSD (~8–12 hours). The brief data for 1P-ETH-LAD shows 6–12 hours total, which overlaps.

---

## History

### Discovery and Early Synthesis

ETH-LAD (the active metabolite of 1P-ETH-LAD) was first synthesized in **1976** by Japanese researchers — Tetsukichi Niwaguchi, Yuji Nakahara, and Hisashi Ishii — in the context of experiments investigating microbial degradation of LSD. This represents the earliest known synthesis of the parent compound.

The **pharmacological characterization** of ETH-LAD, including LSD-like discriminative stimulus properties and SAR data, was published by **Andrew J. Hoffman and David E. Nichols** in 1985 in the *Journal of Medicinal Chemistry* [Ref 16], in a series studying N⁶-alkyl norlysergic acid N,N-diethylamide derivatives. This paper established ETH-LAD as a potent LSD-like hallucinogen with sub-nanomolar receptor affinity.

**1P-ETH-LAD** was a later development emerging on the novel psychoactive substances (NPS) market. **The first published analytical characterization of 1P-ETH-LAD appears in scientific literature in Brandt et al. (2017) [Ref 1]** — the authors explicitly note that "information about 1P-ETH-LAD has not previously been encountered in the scientific literature." It appeared on the research chemical market in the mid-2010s, likely around 2015–2017.

Brandt et al. (2017 [Ref 1]) noted that 1P-ETH-LAD is a **constitutional isomer of 1B-LSD** (1-butanoyl-LSD), meaning both have the same molecular formula (C₂₄H₃₁N₃O₂) but different structural arrangements of the N-1 acyl chain and N⁶ substituents (Brandt et al. 2019 [Ref 3]).

### Research Context

The "Return of the Lysergamides" series by Brandt, Halberstadt, Nichols, and colleagues has been the primary scientific vehicle for characterizing 1P-ETH-LAD and related NPS. Part III of this series (Brandt et al. 2017 [Ref 1]) is the foundational reference for 1P-ETH-LAD. Earlier parts in the series characterized 1P-LSD (Part I [Ref 7]), AL-LAD/LSZ (Part II [Ref 8]), LSM-775 (Part IV [Ref 9]), and 1B-LSD (Part V [Ref 3]).

### Market and Detection History

ETH-LAD itself was detected in paper sheet products in Japan from 2014 to 2017, identified by GC-MS, LC-MS, and NMR in a forensic survey (Tanaka et al. 2020 [Ref 22]). 1P-ETH-LAD, as a more recently synthesized prodrug, appeared somewhat later. Cayman Chemical lists it as an analytical reference standard (CAS 2230715-45-2 [Ref 32]), confirming its commercial availability for forensic reference purposes.

---

## Subjective Effects

**No controlled human pharmacology studies exist for 1P-ETH-LAD or ETH-LAD.** All subjective effects data derive from (a) a large community survey that pooled ETH-LAD with other LSD analogs, and (b) user reports from online psychedelic communities.

### Survey Data (Coney et al. 2017 [Ref 17])

The Global Drug Survey 2016 (N = 96,894) included users of LSD analogues including ETH-LAD. Key findings:
- **93% of LSD analogue users described effects as psychedelic**
- Modal total duration: **8 hours** (not significantly different from LSD)
- Time to peak effects: **2 hours** (not significantly different from LSD)
- Route of administration: **99% oral**
- Source: 55% obtained online
- Compared to LSD: analogue users reported **significantly lower ratings for pleasurable high, strength of effect, comedown, urge to use more, and value for money**

⚠️ Note: Coney et al. (2017) pooled AL-LAD, 1P-LSD, and ETH-LAD together (not disaggregated by substance), so ETH-LAD-specific data cannot be extracted from this study.

### Community Consensus (User-Report Data Only — Labeled as Such)

The following is based on community reports from psychedelic users (PsychonautWiki, Erowid-adjacent sources) — **not controlled studies**. These should be clearly labeled as user-report data in the article:

**ETH-LAD (active form):**
- At low-to-common doses: described as similar to LSD but with more pronounced visual effects and a reportedly "colder" or less emotionally warm headspace
- At higher doses: reported to produce more intense, "algorithmic" and "warped" visual and auditory distortions compared to LSD
- Described as more introspective and analytical, with less emotional charge than LSD
- Visual effects reported as more prominent relative to entactogenic/empathogenic qualities

**1P-ETH-LAD (prodrug form):**
- Community reports describe effects largely identical to ETH-LAD (consistent with prodrug hypothesis)
- Described as moderately to significantly more potent than LSD on a microgram-per-microgram basis (community consensus; not verified in controlled studies)
- More visual and synaesthetic, with a reportedly deeper and less emotionally charged headspace vs LSD

**Duration (community consensus vs seed data cross-check):**
- ETH-LAD: 8–12 hours total (PsychonautWiki)
- 1P-ETH-LAD seed data: 6–12 hours total
- Onset for 1P-ETH-LAD: 30–90 minutes (consistent with prodrug hydrolysis delay vs ETH-LAD's 20–40 min)

The brief's duration data appears consistent with available evidence. The common dose range in the brief (60–100 µg) is slightly narrower than ETH-LAD's community-reported common range (60–150 µg), which may reflect the prodrug's slightly different potency relationship. **Flag for editorial review.**

---

## Safety & Toxicity

### LD50 and Toxic Dose

**No LD50 data exists for 1P-ETH-LAD or ETH-LAD.** No animal lethality studies have been published. The brief correctly notes "toxic dose is unknown." This is consistent with the broader LSD class, for which LD50 data is extremely limited; LSD's LD50 in rodents is in the order of 16.5 mg/kg (IV in rats), but no equivalent data exists for ETH-LAD.

**⚠️ FLAG — Safety critical:** No published LD50 or toxic dose data for 1P-ETH-LAD or ETH-LAD. All dose safety assessments rely on LSD analog class inference.

### Adverse Effects

No controlled safety studies or dedicated toxicity studies have been published for 1P-ETH-LAD or ETH-LAD. The broader lysergamide NPS class context from Luethi & Liechti (2020 [Ref 5]) indicates:
- Intoxication reports with designer drugs including serotonergic psychedelics commonly involve anxiety, panic, paranoia
- Several designer drugs are used concurrently, posing elevated risk
- These substances remain undetected by routine drug screening

### Case Reports

**No published case reports of adverse events, overdose, or toxicity specifically involving 1P-ETH-LAD or ETH-LAD** were found in the literature search. This absence should be stated explicitly.

### Hallucinogen Persisting Perception Disorder (HPPD)

HPPD is a known risk of the LSD class. Multiple reviews and case series establish:
- HPPD is rare but can occur after even a single LSD-class exposure (Martinotti et al. 2018 [Ref 25])
- Two forms: Type 1 (brief flashbacks) and Type 2 (chronic, waxing/waning; Halpern et al. 2018 [Ref 27])
- LSD is one of the most commonly associated substances (Ayyub et al. 2023 [Ref — see PMID 37908914])
- Treatment: clonidine, clonazepam, levetiracetam showed substantial symptom reduction in systematic review (Neven & Blom 2025 [Ref 13])
- Risperidone may paradoxically worsen HPPD
- Benzodiazepines ineffective specifically when HPPD triggered by LSD (Neven & Blom 2025 [Ref 13])
- Flashback phenomena observed in controlled LSD studies (Mueller et al. 2022 [Ref 26])

### Psychological Risks

- Risk of anxiety, panic, and challenging experiences: class-level risk for all 5-HT₂A agonist psychedelics (Nichols et al. 2017 [Ref 21])
- Predisposing factors for adverse reactions include history of psychosis, anxiety disorders, and family history of psychotic illness (Rucker et al. 2018 [Ref — see Ref 29])
- Population-level data: psychedelic use (LSD class) not associated with increased mental health problems in non-psychotic populations (Krebs & Johansen 2013 [Ref 30])

### Cardiovascular Effects

By class analogy with LSD (for which controlled study data exists):
- LSD produces modest increases in heart rate and blood pressure at recreational doses (Holze et al. 2024 [Ref 27])
- No direct cardiovascular safety data for ETH-LAD or 1P-ETH-LAD

### Physical Safety Profile

- LSD class substances regarded as physiologically non-toxic at recreational doses in otherwise healthy individuals (Nichols et al. 2017 [Ref 21])
- No organ toxicity data specific to 1P-ETH-LAD or ETH-LAD
- **⚠️ FLAG:** All physical safety claims for 1P-ETH-LAD are based on structural class inference, not substance-specific evidence.

---

## Harm Reduction

### Testing

- Ehrlich reagent (purple/blue reaction) can identify indole alkaloids including LSD-class compounds; specific differentiation between LSD and analogs requires LC-MS or NMR
- Standard immunoassay drug tests do **not** detect ETH-LAD or 1P-ETH-LAD (Wagmann et al. 2019 [Ref 2]); specific analytical methods needed for forensic identification

### Set and Setting

Class-level harm reduction consistent with LSD applies: controlled environment, trusted company, clear intentions, no mixing with other substances, particularly those with serotonergic activity.

### Contraindications

**⚠️ FLAG — Safety-critical, class inference only:**
- **Personal or family history of psychosis, schizophrenia, or bipolar disorder** (contraindicated for all classical psychedelics)
- **Concurrent serotonergic medications** (SSRIs, SNRIs, MAOIs, tramadol) — serotonin toxicity risk
- **Pregnancy** (no safety data; class-level contraindication)
- **Cardiovascular disease** (sympathomimetic effects; class-level risk)

### Emergency Response

- No ETH-LAD/1P-ETH-LAD-specific emergency protocols exist
- Supportive care is the standard approach for LSD-class adverse reactions
- Benzodiazepines for acute anxiety/agitation (first-line in emergency settings for LSD intoxication)

---

## Tolerance & Dependence

### Tolerance

The brief states: "Buildup: almost immediately after ingestion; Half-life: 3 days; Full reset: 7 days; Cross-tolerances: psychedelic."

This data is consistent with the known tolerance profile of the LSD class. 5-HT₂A receptor downregulation (tachyphylaxis) is the established mechanism (Wallach et al. 2023 [Ref 19]); cross-tolerance with all 5-HT₂A agonist psychedelics is well-documented at the class level. The 3-day half-life and 7-day full reset are community consensus values that align with the LSD class, though specific pharmacological studies for 1P-ETH-LAD or ETH-LAD have not been published.

**⚠️ FLAG:** Tolerance half-life (3 days) and full reset (7 days) for 1P-ETH-LAD are not sourced from published primary data for this specific compound — they represent class inference from LSD literature and community consensus. No primary studies exist.

### Dependence Liability

- LSD class regarded as non-habit-forming and non-addictive (brief states "not habit-forming")
- Population study (Krebs & Johansen 2013 [Ref 30]): no association between LSD/psilocybin/mescaline use and substance use disorders in a nationally representative sample of 130,152 participants
- Compulsive redosing is not a feature of the LSD class; rapid tolerance development physiologically discourages repeated use
- No evidence of physical withdrawal syndrome for LSD-class compounds

### Cross-Tolerance

Full cross-tolerance expected with all classical serotonergic psychedelics (LSD, psilocybin, mescaline, DMT, etc.) via shared 5-HT₂A receptor downregulation mechanism (Wallach et al. 2023 [Ref 19]).

---

## Interactions

### Tramadol — Dangerous (seed data confirmed)

The brief lists tramadol as "dangerous." This is supported by established pharmacology:
- Tramadol has dual mechanism: μ-opioid agonism + monoaminergic activity (serotonin and norepinephrine reuptake inhibition) (Roulet et al. 2021 [Ref 28])
- Tramadol combined with serotonergic agents risks **serotonin syndrome** — potentially life-threatening (Park et al. 2014 [Ref 23])
- Combining tramadol with a 5-HT₂A agonist (ETH-LAD) represents a serious serotonergic synergy risk
- **⚠️ FLAG — Safety critical:** The "dangerous" classification for tramadol is based on class pharmacology (established serotonin syndrome risk), not on documented case reports specifically involving 1P-ETH-LAD or ETH-LAD. No case reports were found.

### Cannabis — Unknown (seed data confirmed)

The brief lists cannabis as "unknown." Community reports suggest cannabis potentiates psychedelic effects and may increase risk of anxiety/paranoia and challenging experiences. No controlled studies on ETH-LAD/cannabis interaction exist. Cannabis + LSD combination is common in recreational use but evidence is primarily observational. Classification as "unknown" is appropriate given absence of controlled data.

### Lithium

**⚠️ FLAG:** Not listed in brief but should be mentioned for completeness. Lithium + LSD-class combination carries well-documented risk of seizures and dangerous interactions. This is a class-level contraindication for all serotonergic psychedelics that should appear in the article even if not in the current interaction list.

### MAOIs

**⚠️ FLAG:** Not listed in brief. MAOI + psychedelic combination increases serotonin syndrome risk and may dramatically potentiate effects. Class-level safety-critical interaction.

### SSRIs/SNRIs

Not listed in brief. SSRIs may reduce or blunt psychedelic effects (pharmacodynamic antagonism at 5-HT₂A) or, paradoxically, in some combinations increase serotonin toxicity risk. Class-level interaction relevant to 1P-ETH-LAD.

---

## Legal Status

### United Kingdom

**ETH-LAD (active metabolite):** Controlled as a **Class A drug** under the Misuse of Drugs Act 1971, inserted into **Schedule 1** to the Misuse of Drugs Regulations 2001 with effect from **7 January 2015** (UK Home Office Circular 001/2015 [Ref 24]). This applies to possession, supply, production, import, and export (all unlawful except under Home Office licence). The 2015 circular also controlled ALD-52, AL-LAD, PRO-LAD, and LSZ in the same instrument.

**1P-ETH-LAD:** As the N⁶-ethyl modification on ETH-LAD makes ETH-LAD Class A, the prodrug 1P-ETH-LAD is not itself scheduled under the Misuse of Drugs Act 1971 as a named compound — however, it is **illegal to produce, supply, or import under the Psychoactive Substances Act 2016** (in force 26 May 2016 [Ref 33]), which covers all psychoactive substances not otherwise exempted.

### Germany

1P-ETH-LAD is controlled under the **NpSG (Neue-psychoaktive-Stoffe-Gesetz, New Psychoactive Substances Act)** as of **18 July 2019**. Production and import with intent to market, administration to another person, and trading are criminal offences. Possession is illegal but not penalized under NpSG (though possession remains potentially subject to other drug laws).

### United States

**Neither ETH-LAD nor 1P-ETH-LAD is specifically scheduled** under the Controlled Substances Act as of the research date. However, the **Federal Analogue Act (21 U.S.C. § 813)** may apply if the substance is intended for human consumption — given structural similarity to LSD (Schedule I), it would be treated as a Schedule I substance when intended for human use. Enforcement risk exists; status remains legally ambiguous.

### Canada

1P-ETH-LAD is **not a controlled substance** in Canada as of 2025 (no specific scheduling identified). ETH-LAD's status in Canada was not confirmed by primary sources — requires further verification.

### Australia

Specific scheduling information for 1P-ETH-LAD in Australia was not confirmed by primary sources in this research. 1P-LSD has been reported as controlled in Australia; 1P-ETH-LAD's status requires verification against the current Poisons Standard (SUSMP).

### Japan

ETH-LAD (not 1P-ETH-LAD specifically) was detected in paper sheet products in Japan between 2014 and 2017 (Tanaka et al. 2020 [Ref 22]). Under Japan's Pharmaceutical and Medical Device Act, substances may be designated as "Designated Substances" (Shitei Yakubutsu); 1P-LSD was controlled in Japan from April 2016. ETH-LAD was under evaluation for legislation at time of the Tanaka 2020 publication. Specific current status of 1P-ETH-LAD in Japan not confirmed.

---

## Clinical Trials

**No registered clinical trials exist for 1P-ETH-LAD or ETH-LAD** (ClinicalTrials.gov search returned no results). This is consistent with the research chemical status of both compounds and the absence of any therapeutic development program.

Clinical trials are active for the parent compound LSD (multiple studies by Liechti group, Basel; MAPS; other groups), but none involve ETH-LAD or 1P-ETH-LAD specifically.

---

## Community Feedback Analysis

**No community feedback was submitted in Part A2 of the brief.**

No community feedback present — standard research directives from Part B applied.

---

## Gaps & Flags

### Critical Gaps

1. **No human pharmacokinetic data** for 1P-ETH-LAD or ETH-LAD. Onset, peak, and duration estimates derive from class analogy (1P-LSD) and community surveys (Coney 2017). All PK claims are inferred.

2. **No direct receptor binding data for 1P-ETH-LAD itself** published. The compound's own binding affinities are inferred from the class-level finding that 1-acyl substitution reduces affinity 1–2 orders of magnitude (Halberstadt 2020 [Ref 4]).

3. **ETH-LAD Ki values (5-HT₂A 5.1 nM, D2 4.4 nM)** were retrieved from secondary web database sources citing Hoffman & Nichols 1985 [Ref 16], a verified DOI. The original paper was not retrieved in full text. The generation agent should flag these values as requiring primary source verification.

4. **No case reports of adverse events or overdose** for 1P-ETH-LAD or ETH-LAD found in any published literature search.

5. **No LD50 or acute toxicity data** for 1P-ETH-LAD or ETH-LAD in any species.

6. **SMILES string** was not returned by PubChem API call; should be retrieved separately for PubChem CID 119025859.

7. **Canada and Australia legal status** for 1P-ETH-LAD not confirmed from primary government sources.

### Safety-Critical Flags

- **Tramadol interaction "dangerous" classification** is based on class pharmacology (serotonin syndrome risk via tramadol's serotonergic mechanism), not specific case reports for 1P-ETH-LAD. The classification is scientifically sound but should be labeled as class-inferred.

- **Dose range values** (threshold 25 µg through Heavy 200+ µg) are community consensus for 1P-ETH-LAD specifically and have not been validated in controlled studies. There is a note-worthy difference between the ETH-LAD common range (60–150 µg per community consensus) and the brief's 1P-ETH-LAD common range (60–100 µg). The broader range may be more appropriate given ETH-LAD user reports; however, without controlled data, the narrower range is a conservative choice.

- **Tolerance values** (half-life 3 days, full reset 7 days) are class-inferred from LSD literature, not substance-specific.

### Areas Relying on Structural Analogy

- Hepatic metabolism via CYP1A2/CYP3A4 (Wagmann 2019 includes 1P-ETH-LAD in S9 study — this is direct data, not analogy)
- Prodrug conversion to ETH-LAD (Brandt 2017 — direct serum study, not analogy)
- Physical safety profile at recreational doses (LSD class inference; no ETH-LAD/1P-ETH-LAD specific data)
- Cardiovascular effects (LSD class inference)
- Psychological risk profile (LSD class inference)
- Tolerance half-life/reset values (LSD class consensus)
- LD50 unknown (no data for any species)

### Missing Interactions That Should Be Added

The article should note the following drug interactions based on class pharmacology (not in current brief interaction list):
- **Lithium:** dangerous; seizure risk with LSD class (well-documented class-level interaction)
- **MAOIs:** potentially dangerous; serotonin toxicity risk + potentiation
- **SSRIs/SNRIs:** may reduce effects OR increase serotonin syndrome risk depending on mechanism; pharmacodynamic 5-HT₂A antagonism by chronic SSRI use can blunt effects

---

## Key References Summary

| Ref | Citation | Key Data |
|---|---|---|
| [Ref 1] | Brandt et al. 2017, Drug Test Anal | First published characterization of 1P-ETH-LAD; prodrug hypothesis |
| [Ref 2] | Wagmann et al. 2019, Anal Bioanal Chem | In vitro metabolism: CYP1A2/CYP3A4; metabolite mapping |
| [Ref 3] | Brandt et al. 2019, Drug Test Anal | 1B-LSD (constitutional isomer); HTR data |
| [Ref 4] | Halberstadt et al. 2020, Neuropharmacology | 1-acyl reduces receptor affinity 1-2 orders magnitude |
| [Ref 5] | Luethi & Liechti 2020, Arch Toxicol | Designer drugs review; NPS adverse effects |
| [Ref 6] | Brandt et al. 2024, Drug Test Anal | EIPLA/ETH-LAD isomer; confirms ETH-LAD produces psychedelic effects in humans |
| [Ref 7] | Brandt et al. 2016, Drug Test Anal | 1P-LSD Part I; closest 1-acyl analog; prodrug framework |
| [Ref 11] | Grumann et al. 2020, Drug Test Anal | Human PK of 1P-LSD; ~100% LSD bioavailability |
| [Ref 13] | Neven & Blom 2025, Harv Rev Psychiatry | HPPD systematic review; treatment |
| [Ref 16] | Hoffman & Nichols 1985, J Med Chem | ETH-LAD original pharmacology; binding affinities |
| [Ref 17] | Coney et al. 2017, Hum Psychopharmacol | GDS 2016; ETH-LAD in user survey |
| [Ref 19] | Wallach et al. 2023, Nat Commun | Gq signaling → psychedelic effects; tolerance mechanism |
| [Ref 24] | UK HO Circular 001/2015 | ETH-LAD Class A UK from Jan 2015 |
| [Ref 30] | Krebs & Johansen 2013, PLoS ONE | No mental health harm from psychedelic use |